AMENDED AND RESTATED FORBEARANCE AGREEMENTForbearance Agreement • November 9th, 2010 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • New York
This AMENDED AND RESTATED FORBEARANCE AGREEMENT (this “Agreement”) is made and entered into as of November 4, 2010, by and among ANGIOTECH PHARMACEUTICALS, INC., a corporation organized under the laws of the Province of British Columbia, Canada (“Parent”), each of Parent’s Subsidiaries identified as a “Borrower” on the signature pages hereof (such Subsidiaries, each a “Borrower”, and collectively, jointly and severally, the “Borrowers”), the Lenders (as defined in the Credit Agreement referred to below) listed on the signature pages hereof and WELLS FARGO CAPITAL FINANCE, LLC, a Delaware limited liability company formerly known as Wells Fargo Foothill, LLC, in its capacity as arranger and administrative agent (“Agent”) for the Lenders.
FOURTH AMENDMENT TO CREDIT AGREEMENTCredit Agreement • November 9th, 2010 • Angiotech Pharmaceuticals Inc • Surgical & medical instruments & apparatus • New York
This Fourth Amendment to Credit Agreement, dated as of November 4, 2010 (this “Agreement”), is entered into by and among Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of the Province of British Columbia, Canada (“Parent”), each of Parent’s Subsidiaries identified on the signature pages hereto (such Subsidiaries are referred to hereinafter each individually as a “Borrower”, and collectively as the “Borrowers”), Wells Fargo Capital Finance, LLC, a Delaware limited liability company formerly known as Wells Fargo Foothill, LLC (“Foothill”), as administrative agent for the Lenders (in such capacity, the “Agent”), and the lenders named on the signature pages hereto (the “Lenders”).
